Characteristics of Ongoing and Unpublished Studies (n = 42)
| Register ID | Acronym | Medical condition | Indication | Design | Estimated enrolment | Primary outcome | Estimated study completion date (first enrollment) | Country |
| ACTRN 12609000665235 | OES2008 | Adenocarcinoma of the esophagus or gastroesophageal junction, invasive | Restaging (interim response assessment) | Enrichment | 150 | Histologic response | (July 2009) | Aus |
| NCT00146458 | Cervical cancer, advanced | Staging | MBSD | 200 | DFS, OS | December 2007 | Taiwan | |
| NCT00895349 | PET LACE Trial | Cervical cancer, locally advanced | Staging | MBSD | 288 | Change in management | October 2017 | Can |
| NCT01075412 | Cervical cancer, uterine cervical neoplasms | Radiotherapy planning | MBSD | 30 | 3′-deoxy-3′-18F-fluorothymidine uptake | September 2013 | U.S.A. | |
| NCT00823810 | RESCORE | Colorectal cancer, advanced | Restaging | MBSD | 150 | OS | February 2011 | Fin |
| NCT00265356 | PETCAM | Colorectal cancer, liver Metastases | Staging | MBSD | 404 | Change in management | April 2010/2015 | Can |
| ISRCTN97323814 | TRAVASTIN-1 | Colorectal cancer, metastatic | Stratification | Interaction | 25 | PFS | (November 2009) | U.K. |
| NCT00199654 | Colorectal cancer, stage II and III | Follow-up | MBSD | 376 | Time to relapse | (February 2004) | F | |
| NCT00624260 | ITEP | Colorectal cancer, stage III and IV | Follow-up | MBSD | 240 | Decrease of noncurative recurrences | December 2013 | F |
| NCT00329706 | MCI-ID | Dementia | Primary diagnosis | MBSD | 710 | Cognitive function | January 2016 | U.S.A. |
| NCT00367341 | Depressive disorder, major | Stratification | Interaction | 100 | Remission | June 2010 | U.S.A. | |
| DRKS00000633 | GLIAA-Pilot | GBM, recurrent | Radiotherapy planning | MBSD | 30 | AA-PET/MRI nonoverlap | (December 2010) | Ger |
| NCT00500188 | GIST | Stratification | Interaction | 48 | DFS | July 2011 | U.S.A. | |
| NCT00784537 | HD0801 | HD | Restaging (interim response assessment) | Enrichment | 300 | PFS | December 2014 | I |
| NCT00736320 | HD 16 | HD | Restaging (interim response assessment) | MBSD | 1,100 | PFS | November 2013 | Ger |
| NCT00795613 | HD0607 | HD, advanced | Restaging (interim response assessment) | Enrichment | 450 | PFS | July 2012/2015 | I |
| NCT00515554 | HD18 | HD, advanced stages | Restaging (interim response assessment) | Enrichment | 1,500 | PFS | May 2012 | Ger |
| NCT01092182 | HD, Burkitt lymphoma/leukemia (BL) | Stratification | Interaction | 73 | PFS, EFS and OS | March 2018 | U.S.A. | |
| NCT00169598 | TEPELY | HD, NHD | Restaging | MBSD | 80 | Change in management | (February 2002) | F |
| NCT00433433 | EORTC-GELA-IIL | HD, stage I and II | Restaging (interim response assessment) | MBSD | 1,600 | PFS | (October 2006) | NL |
| NCT00943423 | RAPID | HD, stage Ia and IIa | Restaging (interim response assessment) | Enrichment | 400 | PFS | December 2009 | U.K. |
| ISRCTN99811594 | 18F-FDG PET | HD, stage Ia to IIa | Restaging | Enrichment | 400 | PFS | (October 2003) | U.K. |
| NCT00678327 | U.K. NCRI Lymphoma Group | HD, stage II - intravenous | Restaging | MBSD | 1,200 | PFS | September 2012 | U.K. |
| ACTRN 12608000639325 | HD0607 | HD, stage IIb to IVb | Restaging (interim response assessment) | Enrichment | 450 | PFS | (June 2008) | I |
| NCT00554164 | PETAL | NHD, aggressive | Restaging (interim response assessment) | Enrichment | 696 | Time to treatment failure | December 2014 | Ger |
| NCT01285765 | NHD, DLBCL with low risk | Restaging (interim response assessment) | Enrichment* | 420 | PFS | January 2017 | F | |
| NCT01287390 | HNC | Radiotherapy planning | MBSD | 100 | Treatment-induced dysphagia | December 2015 | Be | |
| NCT00720070 | HNC | Restaging | MBSD | 560 | OS | Aug 2012 | U.K. | |
| ISRCTN13735240 | PET-NECK | HNC, locally advanced | Staging | MBSD | 560 | OS | (April 2007) | U.K. |
| ISRCTN49573946 | BOOST | Lung cancer | Staging | MBSD | 168 | Time to treatment decision | (April 2008) | U.K. |
| NCT00199615 | NSCLC | Follow-up | MBSD | 73 | DFS | December 2006 | F | |
| NCT00697333 | PET-Plan | NSCLC, advanced | Radiotherapy planning | MBSD | 394 | Local PFS | February 2013 | Ger |
| NCT01170923 | NSCLC, advanced | Restaging (interim response assessment) | MBSD | 100 | Response rate | August 2010 | South Korea | |
| NCT00840749 | STARS | NSCLC, stage I | Radiotherapy planning (CyberKnife; Accuray Inc.) | Interaction | 1,030 | OS | December 2013 | U.S.A. |
| NCT01024829 | BTV Boost | NSCLC, stage II and III | Radiotherapy planning | MBSD | 106 | Local PFS | August 2013 | NL |
| NCT00533949 | NSCLC, stage III | Radiochemotherapy planning | Interaction | 500 | OS | January 2014 | U.S.A. | |
| NCT00136864 | PET-START | NSCLC, stage III | Staging | MBSD | 400 | Upstaging by PET | May 2011 | Can |
| NCT01050426 | PERU | Pancreatic cancer, locally advanced | Stratification | Interaction | 90 | OS | September 2015 | U.K. |
| NCT00313560 | Pancreatic cancer, stage I or II | Stratification | Interaction | 60 | Pharmacodynamics | December 2008 | Aus | |
| ACTRN 12608000641392 | Prostate cancer | Staging and restaging | MBSD | 100 | Change in management | (December 2008) | Aus | |
| NCT00964275 | Thromboembolism, unspecified adult solid tumor | Primary diagnosis | MBSD | 310 | Number of cancers diagnosed | March 2011 | F | |
| NCT01240590 | Thyroid cancer, anaplastic | Stratification | Interaction | 70 | Dose-limiting toxicity | September 2012 | U.S.A. |
* This study applied noninferiority design.
Aus = Australia; MBSD = marker-based strategy design; DFS = disease-free survival; OS = overall survival; Can = Canada; Fin = Finland; PFS = progression-free survival; U.K. = United Kingdom; F= France; GBM = glioblastoma multiforme; AA = amino-acid; Ger = Germany; GIST = gastrointestinal stromal tumor; HD = Hodgkin disease; I = Italy; EFS = event-free survival; NHD = non-Hodgkin disease; NL = Netherlands; DLBCL = diffuse large B-cells non-Hodgkin lymphoma; HNC = head and neck cancer; Be = Belgium.